Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KELI-103
- Development stage
- Preclinical
- Lead developer
- Keli Therapeutics
- Modality
- Stem Cell Therapies → Cell Therapies
01
Overview
KELI-103 is an allogeneic, off-the-shelf cell therapy being developed by KELI Therapeutics for the treatment of moderate to severe acute respiratory distress syndrome (ARDS). Derived from ethically sourced postpartum placental tissue, the therapy consists of placental mesenchymal stromal cells produced using a scalable 2D/3D bioreactor manufacturing process (the KELI-100 platform). KELI-103 exerts its therapeutic effects through immunomodulatory and regenerative mechanisms, specifically by suppressing pro-inflammatory cytokine activation, reducing lung inflammation, promoting tissue repair, and preventing fibrosis. It is currently in the preclinical stage of development.
Beyond the preview
Go deeper on KELI-103.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KELI-103.